Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 1878
  • Home
  • Print this page
  • Email this page

   Table of Contents      
Year : 2013  |  Volume : 61  |  Issue : 3  |  Page : 136-138

Intravitreal bevacizumab monotherapy for treatment-naïve polypoidal choroidal vasculopathy

1 Smt. Kanuri Santhamma Retina Vitreous Service, L V Prasad Eye Institute, Hyderabad, India; Shiley eye center, University of California, San Diego, USA
2 Smt. Kanuri Santhamma Retina Vitreous Service, L V Prasad Eye Institute, Hyderabad, India

Date of Web Publication21-Mar-2013

Correspondence Address:
Raja Narayanan
Smt. Kanuri Santhamma Retina Vitreous Service, L.V. Prasad Eye Institute, Kallam Anji Reddy Campus, Banjara Hills, Hyderabad-500 034, India

Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0301-4738.109390

Rights and Permissions

How to cite this article:
Chhablani JK, Narula R, Narayanan R. Intravitreal bevacizumab monotherapy for treatment-naïve polypoidal choroidal vasculopathy. Indian J Ophthalmol 2013;61:136-8

How to cite this URL:
Chhablani JK, Narula R, Narayanan R. Intravitreal bevacizumab monotherapy for treatment-naïve polypoidal choroidal vasculopathy. Indian J Ophthalmol [serial online] 2013 [cited 2021 Apr 11];61:136-8. Available from: https://www.ijo.in/text.asp?2013/61/3/136/109390

Dear Editor,

Polypoidal choroidal vasculopathy (PCV) is primarily a choroidal vascular disease, which can lead to acute severe visual loss secondary to massive submacular or vitreous hemorrhage.

Various treatment modalities, such as direct thermal laser photocoagulation, tissue plasminogen activator (t-PA) injection with gas displacement, submacular surgery and macular translocation surgery have been proposed. Photodynamic therapy (PDT) with verteporfin has shown good results for PCV, but extensive subretinal hemorrhages and exudation limits its application. [1] Favorable results have been reported with combined therapy, including PDT and intravitreal bevacizumab (IVB), to treat PCV. [2]

We evaluated nine eyes of eight patients with PCV who were treated with IVB monotherapy. We excluded patients that had any previous treatment for PCV or wet age-related macular degeneration (AMD) in the study or contralateral eye.

All participants received a comprehensive ocular examination including digital fluorescein angiography (FA), indocyanine green angiography (ICGA) and optical coherence tomography (OCT) at baseline, and at 3-monthly interval visits till last follow-up. IVB injection was performed as per standard protocol. Repeat treatment was performed every 4 weeks if the OCT showed persistent pigment epithelial detachment (PED)/subretinal fluid (SRF) or active polypoidal lesion on fundus fluorescein angiography (FFA)/ICGA.

The mean age was 60.6 years and 37.5% of the patients were female. At baseline, the median Snellen best corrected visual acuity (BCVA) was 20/2000 (range 20/30-20/10,000). The mean follow-up duration was 8.4 months (range 4-12 months).

All eyes showed resolution of subretinal hemorrhage, PED [Figure 1] and angiographic activity [Figure 2], but persistence of polypoidal lesion was noted in three eyes. At the last follow-up, the median Snellen BCVA was 20/100 (range 20/25-20/400). The mean log MAR BCVA showed a statistically significant improvement from 1.41 to 0.63 (P = 0.04). Seven (77.7%) eyes showed significant improvement in visual acuity, with mean number of line improvement of 6.5. The remaining two eyes maintained the baseline visual acuity till last follow-up. The mean number of injections was 2.3. The mean longest treatment-free period was 5.88 months. No significant systemic or ocular side-effects were observed in any of the eyes receiving IVB injections.
Figure 1: Fundus photo at baseline (a) shows hemorrhagic pigment epithelial detachment (PED) involving the fovea with subretinal hemorrhage. (b) (at 1-month follow-up) Reduction in the PED with decrease in subretinal hemorrhage. (c) (at 3-month follow-up) Disappearance of subretinal hemorrhage and PED. (d) OCT at baseline shows a PED with intraretinal cystic fluid at the edge of the PED. (e) (At 1-month follow-up) and (f) (at 3-month follow-up) Significant reduction in the height of the PED on OCT

Click here to view
Figure 2: Indocyanine green angiographic images (a) before treatment and (b) 1 year after treatment, showing regression of polyps (arrows) after treatment

Click here to view

In our study, mean BCVA improvement of 2 or more lines was seen in 72% of the patients, and the remaining 28% showed a stabilization of visual acuity at mean follow-up of 8.4 months. Kokame et al., [3] reported stabilization of vision at 6 months, with monthly intravitreal injection of ranibizumab in PCV.

Lai et al., reported stabilization of vision and reduction in exudative detachment with intravitreal bevacizumab, but a limited role in regression of polypoidal lesions in ICGA. Persistent lesions were treated with PDT. [4] In our study, persistent lesions were closely followed-up, which did not bleed again during the follow-up. Complete regression of polypoidal lesion in ICGA may not be the therapeutic target, but close follow-up is mandatory.

In conclusion, our study demonstrated that IVB injection helps to improve or maintain the vision in patients with symptomatic treatment-naïve PCV.

  References Top

Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y, et al. Photodynamic therapy with vertiporfin for symptomatic polypoidal choroidal vasculopathy. Ophthalmology 2004;111:1576-84.  Back to cited text no. 1
Sato T, Kishi S, Matsumoto H, Mukai R. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy. Am J Ophthalmol 2010;149:947- 54.e1.  Back to cited text no. 2
Kokame GT, Yeung L, Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br J Ophthalmol 2010;94:297-301.  Back to cited text no. 3
Lai TY, Chan WM, Liu DT, Luk FO, Lam DS. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br J Ophthalmol 2008;92:661-6.  Back to cited text no. 4


  [Figure 1], [Figure 2]

This article has been cited by
1 Polypoidal choroidal vasculopathy: An update on therapeutic approaches
Wong, R.L.M., Lai, T.Y.Y.
Journal of Ophthalmic and Vision Research. 2013; 8(4): 359-371


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
Article Figures

 Article Access Statistics
    PDF Downloaded160    
    Comments [Add]    
    Cited by others 1    

Recommend this journal